Actively including ulcerative colitis studies

Anthem-UC:

Evaluates the efficacy and safety of JNJ-77242113 (an oral anti-IL23) for the treatment of moderately to severely active ulcerative colitis

Galocean:

A prospective, non-interventional cohort study of the effectiveness and safety of filgotinib in adult patients with moderately to severely active ulcerative colitis

ABX464-105:

Evaluates the efficacy and safety of ABX464 (obefazimod) for treatment in subjects with moderately to severely active ulcerative colitis

M21-446:

An open-Label study to evaluate the efficacy and safety of ABBV-668 (an anti-RIPK1) in subjects with moderate to severe ulcerative colitis

Landos NX-13-201:

Evaluates the clinical activity and safety of oral NX-13 (activates NLRX1)  in participants with moderate to severe ulcerative colitis

Amgen:

Evaluates the safety and efficacy of Efavaleukin Alfa (an IL2 fusion protein) therapy in subjects with moderately to severely active ulcerative colitis

Remidy study:

Drug repurposing - Statins as microbiota modulating agents in ulcerative colitis

3TR:

A multicentre prospective longitudinal study to evaluate molecular mechanisms of non-response to treatments, relapses and remission in patients with inflammatory bowel disease receiving first time standard of care biological treatment.

Immuniverse:

A multicentre longitudinal observational study to evaluate biomarkers and mechanistic principles in moderate to severe ulcerative colitis patients treated with different targeted therapies

Tabasco: Intestinal bowel ultrasound in acute severe ulcerative colitis